Defense Health Research Protected in Final FY18 National Defense Authorization Act
November 9, 2017 – WASHINGTON: Thanks to the nationwide grassroots advocacy led by the Defense Health Research Consortium (DHRC) and its allied organizations, the final House-Senate conference report to the fiscal year 2018 National Defense Authorization Act will not include …
Answer ALS Partnership
The Les Turner ALS Foundation is very pleased to announce the Les Turner ALS Research and Patient Center at Northwestern Medicine as the newest member of the single largest coordinated and collaborative effort to end ALS in the history of …
A Message from Our Senators
We thank our Illinois Senators Dick Durbin and Tammy Duckworth for their support of our annual ALS Walk for Life on Saturday, September 16 at Soldier Field. We commend their efforts in advocating for ALS research and patient care. Learn …
MT Pharma America Announces FDA Approval of RADICAVA™ (Edaravone)
Just today, we learned the FDA has approved the first new drug for ALS in 22 years! The new drug is called Radicava and has been demonstrated to slow decline of physical function by 33 percent. The timing of this …
FDA Accepts New Drug Application Filing for Edaravone to Treat ALS
Mitsubishi Tanabe Pharma Corporation has announced that the FDA accepted the company’s New Drug Application for edaravone (MCI-186) which is an intravenous treatment for ALS. Based on the Prescription Drug User Fee Act, a decision is expected to be made …
ALS Walk for Life Sponsor Announces New Collaboration
The Les Turner ALS Foundation is happy to share great news about one of our ALS Walk for Life event sponsors, Cytokinetics. The drug development company has finalized a deal to collaborate with global pharma company, Astellas to conduct further research …
